Segall Bryant & Hamill LLC Has $28.61 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Segall Bryant & Hamill LLC boosted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 352.4% during the third quarter, HoldingsChannel.com reports. The firm owned 157,144 shares of the company’s stock after acquiring an additional 122,407 shares during the period. Segall Bryant & Hamill LLC’s holdings in Krystal Biotech were worth $28,605,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its stake in Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after acquiring an additional 93 shares during the last quarter. Jamison Private Wealth Management Inc. bought a new position in shares of Krystal Biotech during the 2nd quarter valued at $28,000. Key Financial Inc acquired a new stake in shares of Krystal Biotech in the 2nd quarter valued at $28,000. Blue Trust Inc. boosted its holdings in Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after purchasing an additional 163 shares in the last quarter. Finally, Values First Advisors Inc. bought a new stake in Krystal Biotech in the third quarter worth $53,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Trading Up 1.3 %

KRYS stock opened at $177.85 on Wednesday. The stock has a market cap of $5.11 billion, a PE ratio of 100.48 and a beta of 0.82. The stock has a 50-day moving average price of $180.59 and a two-hundred day moving average price of $181.90. Krystal Biotech, Inc. has a 1 year low of $99.00 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. During the same period in the previous year, the firm posted ($0.67) EPS. The company’s revenue for the quarter was up 879.9% on a year-over-year basis. On average, analysts forecast that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. This trade represents a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 14.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on KRYS. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Stifel Nicolaus boosted their target price on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Chardan Capital boosted their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $197.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).